ATE309004T1 - System für transdermale verabreichung mit niedrigem fluss für hochwirksame medikamente - Google Patents

System für transdermale verabreichung mit niedrigem fluss für hochwirksame medikamente

Info

Publication number
ATE309004T1
ATE309004T1 AT94925757T AT94925757T ATE309004T1 AT E309004 T1 ATE309004 T1 AT E309004T1 AT 94925757 T AT94925757 T AT 94925757T AT 94925757 T AT94925757 T AT 94925757T AT E309004 T1 ATE309004 T1 AT E309004T1
Authority
AT
Austria
Prior art keywords
delivery system
low flow
transdermal delivery
highly potent
potent drugs
Prior art date
Application number
AT94925757T
Other languages
English (en)
Inventor
Eric J Roos
Chia-Ming Chiang
Tsung-Min Hsu
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22300358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309004(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE309004T1 publication Critical patent/ATE309004T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94925757T 1993-08-09 1994-08-05 System für transdermale verabreichung mit niedrigem fluss für hochwirksame medikamente ATE309004T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/104,414 US5554381A (en) 1993-08-09 1993-08-09 Low flux matrix system for delivering potent drugs transdermally
PCT/US1994/008883 WO1995004554A1 (en) 1993-08-09 1994-08-05 Low flux transdermal potent drug delivery system

Publications (1)

Publication Number Publication Date
ATE309004T1 true ATE309004T1 (de) 2005-11-15

Family

ID=22300358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925757T ATE309004T1 (de) 1993-08-09 1994-08-05 System für transdermale verabreichung mit niedrigem fluss für hochwirksame medikamente

Country Status (13)

Country Link
US (1) US5554381A (de)
EP (1) EP0716615B2 (de)
JP (1) JPH09505554A (de)
AT (1) ATE309004T1 (de)
AU (1) AU679557B2 (de)
CA (1) CA2169164A1 (de)
DE (1) DE69434537T3 (de)
DK (1) DK0716615T4 (de)
ES (1) ES2249763T5 (de)
FI (1) FI960556A7 (de)
NO (1) NO960487D0 (de)
NZ (1) NZ271797A (de)
WO (1) WO1995004554A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
AU2746397A (en) * 1996-04-30 1997-11-19 Theratech, Inc. Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19830651A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
ES2270746T3 (es) * 2001-03-16 2007-12-01 Alza Corporation Parche transdermico para administrar fentanilo.
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1547600B1 (de) 2002-08-09 2013-02-13 Teikoku Seiyaku Co., Ltd. Estradiol enthaltendes Pflaster
ATE492636T1 (de) 2002-10-22 2011-01-15 Eisai R&D Man Co Ltd Spezifisch in postmitotischen dopamin- produzierenden neuronalen vorläuferzellen exprimiertes gen
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JP4914826B2 (ja) * 2005-02-28 2012-04-11 久光製薬株式会社 経皮吸収製剤
WO2006135785A2 (en) * 2005-06-10 2006-12-21 Medical College Of Georgia Research Institute Compositions and methods for treating immune disorders
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8734413B2 (en) 2007-08-03 2014-05-27 Kimberly-Clark Worldwide, Inc. Packaged body adhering absorbent article
US7947027B2 (en) 2007-12-28 2011-05-24 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
US8672911B2 (en) 2007-08-03 2014-03-18 Kimberly-Clark Worldwide, Inc. Body adhering absorbent article
MY154027A (en) * 2007-10-15 2015-04-30 Alza Corp Once-a-day replacement transdermal administration of fentanyl
WO2009110351A1 (ja) 2008-03-03 2009-09-11 久光製薬株式会社 経皮吸収製剤
US11147722B2 (en) * 2008-11-10 2021-10-19 Kimberly-Clark Worldwide, Inc. Absorbent article with a multifunctional acrylate skin-adhesive composition
US10022468B2 (en) 2009-02-02 2018-07-17 Kimberly-Clark Worldwide, Inc. Absorbent articles containing a multifunctional gel
EP2459184A1 (de) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation der sgk1-expression bei th17-zellen zur modulation von th17-vermittelten immunreaktionen
EP2556082B1 (de) 2010-04-08 2017-02-22 Emory University Substituierte androst-4-en-dione
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
PH12014501000A1 (en) * 2011-11-04 2014-06-09 Agile Therapeutics Inc Dermal delivery compositions and methods
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
CA2924141C (en) 2013-08-22 2022-06-07 The General Hospital Corporation 5-amino 4-cyano substituted oxazole and thiazole derivatives as inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
EP3303286B1 (de) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
CN108349968A (zh) 2015-07-28 2018-07-31 维奥梅生物科学私人有限公司 抗菌治疗剂和预防剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
CA2065311C (en) * 1989-09-08 2000-01-11 Chia-Ming Chiang Solid matrix system for transdermal drug delivery
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.

Also Published As

Publication number Publication date
ES2249763T5 (es) 2010-02-01
DE69434537T2 (de) 2006-07-20
AU7556294A (en) 1995-02-28
EP0716615A4 (de) 1997-06-11
DE69434537D1 (de) 2005-12-15
FI960556L (fi) 1996-03-11
CA2169164A1 (en) 1995-02-16
EP0716615A1 (de) 1996-06-19
EP0716615B1 (de) 2005-11-09
EP0716615B2 (de) 2009-10-21
WO1995004554A1 (en) 1995-02-16
FI960556A0 (fi) 1996-02-07
US5554381A (en) 1996-09-10
AU679557B2 (en) 1997-07-03
DK0716615T3 (da) 2006-02-20
FI960556A7 (fi) 1996-03-11
NO960487L (no) 1996-02-06
JPH09505554A (ja) 1997-06-03
NZ271797A (en) 1997-12-19
DE69434537T3 (de) 2010-04-15
DK0716615T4 (da) 2009-12-14
NO960487D0 (no) 1996-02-06
ES2249763T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
ATE309004T1 (de) System für transdermale verabreichung mit niedrigem fluss für hochwirksame medikamente
EP0033615B1 (de) Therapeutisches System zum Zuführen von Arzneimitteln zur Haut
NO20074292L (no) Anvendelse av buprenorfin i polymermatriks og leveringssystemer
EP0279977A3 (de) Transdermale Verabreichung von Progesteron, Östradiolestern und deren Mischungen
NZ316026A (en) A transdermal therapeutic system (a hormone patch) in which drugs are contained which are released into the skin comprising a backing film and a pressure sensitive adhesive
GR3036144T3 (en) Transdermal delivery device
KR910700044A (ko) 에스트로겐/프로게스틴 경피용량 단위, 시스템 및 방법
NO852966L (no) Utleveringsanordning for foerste ordensutlevering av en aktiv bestanddel i en opploesningsvaeske, og fremgangsmaate for fremstilling av denne.
CA2027053A1 (en) Estrogen-Containing Active Substance Plaster
FI951424A7 (fi) Styreeni-isopreenistyreeni-kopolymeeriin perustuva transdermaalinen matriisijärjestelmä estrogeenin ja/tai progestogeenin antamiseksi
CA2153572A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
AU692042B2 (en) Transdermal system for the simultaneous delivery of a number of active principles
CA2114936A1 (en) Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
GR3018303T3 (en) Transdermal estradiol delivery system.
PL307786A1 (en) Plaster for percutaneous administration of systemically acting steroid hormones
PT1003477E (pt) Sistema terapeutico transdermico (tts), contendo polimeros de (met)acrilato com grupos amonio para administracao de levonorgestrel
HUP0102498A2 (hu) Szteroid hormont és kristályosodási inhibitort tartalmazó transzdermális rendszer
WO1997020582A3 (en) Transdermal patch for comparative evaluations
ES2165232T3 (es) Sistema terapeutico transdermico (tts) que contiene oxibutinina.
TW273516B (en) Adhesive matrix-type transdermal therapeutic set for motion sickness

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0716615

Country of ref document: EP

REN Ceased due to non-payment of the annual fee